Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like they filled a position. Will have to check the internet archive later to verify which one it was.
Next Week? vs. Cash for Gold scream sushi & the other self-interested & longtime stock prognosticators on this board Many competitors reported failed trials during HN month. While it would have been sweetly poetic to have had CVM report Multikine as a cure for HN on the last day of the month, it was always unlikely. With that being said, if the Multikine drug trial had failed, there was no shame to be found in reporting in chorus with the competitors. As such, it seems multikine may very well have proven to be an effective treatment for HN (I can't wait to learn if its effectiveness derives from its cytokine ability to disrupt cancer's energy use for cell division & metastasis thus allowing cell suicide to finally complete in host cells thereby effectively wounding the cancer with breaches penetrable by various healthy immune cells & platelets)
Joe Manchin has already stated that he will not vote for the infrastructure package if the tax rate is changed to those numbers. I'd expect the capital gains tax increase to be lowered to 25% but include a broader base of $750.000 & allow an increased home sales exclusion for single persons up to $375,000 & $750,000 for married couples. Also, I'd the bet the top income tax bracket settles at just over 38%
If CVM is sold, its CEO & board members will be highly recruited for top tier corporate governance positions that would allow them to earn a second fortune.
Exercising options on the precipice of data readout would be an ACTUAL example of illegal insider trading (and also stupid because any buyout will include Cash Plus for those options)
Multikine, the MegaBlockBuster Head & Neck Cancer drug from Cel-Sci, is so close to data readout that the CEO is now declining interviews from friendly financial media.
I look forward to seeing a state of the art cgi animated diagnostic presentation of their findings.
Tumor microenviromental response to treatment is fascinating. Looking forward to learning what Cel-Sci has discovered about tumor secretions in response to its immunotherapy treatment (i.e., what are their enzymatic/protein properties? How are they agonistically effective in responding to the body's immune responders [T Cells, Neutrophils, B Cells, Scavenger Cells, Platelets, etc]?)
Arm flailing attention seeking by the CEO is quite unusual. Legally, he can do anything but communicate that he has data, knows its results, & unofficially shares them or the release date. If he makes it onto Forbes list, what are his philanthropic intentions?
A probable Stock Plus Cash buyout converts all options & spares C-suite executives of the expense & unnecessary price trifling . When giving serious thought to this form 4 episode, I am left to conclude that it is a bit of a running joke in the respected hallways along San Tomas.
There is no reason he could not exercise options at their set prices by selling fewer shares of the company's stock he already held when its price reached its post data readout peak. His reasons are irrelevant to the risk decision I've fully committed myself to here.
I used an aspirational example of noble merit that I thought was contextually frivolous given the expected immediacy of data readout
So it is 10k = $240,000 of love showered on his children & grandchildren (education???) ..I've finally seen the actual form 4.
His Senior Vice President of Regulatory Affairs salary is sufficient for any everyday whim of elite life & cumulative planning.....
It was 1000 shares 1k = $24,000 = PRESENTS ..He still has 63,108 = $1.5 million ( + options )
I had thought StockVader would have made an appearance by now.
In accordance with my wild assumption about the planned & approved use of a commonplace 120 calendar for data statistical analysis, negative results were most likely to be reported this afternoon and that outcome window is now closed.
I am uninterested in NWBO comparisons that are dependent upon the continuing unknowns of whether statistical analysis of the data from its clinical trial has been arranged & enacted.
On day 121 of post data lock analysis cel-sci listed an employment opening for a supervisor of Quality Control. Did this signal the beginning for the evaluation of statistical analysis by the company (its scientists & legal team included) for its formulation & drafting of its study results public disclosure?
The idea of a time indefinite contract between the CRO & its contracted independent statistical reviewers is unfathomable.
There really is no reason why CVM or Kersten should not know or have had input on CRO affiliated contract deadlines.
IF I were a CEO who had known to expect a substantial increase in workload & global business travel as a result company milestones, I would time such expectations to coincide with when I was freshest...
Or so I've gambled in continued anticipation of the research investment market efficiency importance of publishing & presentation to the American Society of Clinical Oncology.
I'd think that the 2500 smarttanks mentioned in the LOI are primarily intended for their installation & tech specialists whose input is essential to ensuring tech manual specificity.
Is the IOT SmartTank App field test more about established & standardized IOT reliability or about the chemical company determining finer details for service product marketing & giving their legal department time to codify necessary changes to service contracts?
I am inclined to expect April revenues to have a noticeable bump up solely in response to the "field tests".
Perspective: What is the over/under for revenue exceeding $5 million for the month of March?
How long can you hold your breath?
Perspective: What is the over/under for revenue exceeding $5 million for the month of March?
How long can you hold your breath?
$ALYI has priced itself with its $100 million RevoltToken transfer ownership plan. Isn't $IQST the most likely partner/ suitor with the managerial competence to profitably bring the bike to market? Why should $IQST limit its interest in the project to $200/ battery on a product whose current ownership has an extremely insecure path for realizing profitable production?
$ALYI has priced itself with its $100 million RevoltToken transfer ownership plan. Isn't $IQST the most likely partner/ suitor with the managerial competence to profitably bring the bike to market? Why should $IQST limit its interest in the project to $200/ battery on a product whose current ownership has an extremely insecure path for realizing profitable production?
I wasn't wr, wr, wro, wro...
December 7th, 2020 PR did in fact make march 18th a nearly drop dead date for publishing study findings. Now should I weigh with emphasis how the late data may de-prioritize placement at ASCO in June as an indicator of increased risk? Will short traders prop the stock price up to play bagholder games?
Probably far left field thinking, but doesn't ASCO late abstract submission criteria explicitly exclude TLD? https://meetings.asco.org/am/late-breaking-data-submission-guidelines
It would be shameful, regardless of study results, if $CVM's multikine study did not factor into ASCO this June.
So if I formed a developmental stage pharmaceutical company founded on the notion that a patented retinoic compound that has crossed the blood brain barrier & produced neurogenesis by regulating N-acetylaspartate balance in rat models & then funded my research with share selling loan agreements requiring me to contract a Transfer Agent earning commissions based upon the daily volume of shares exchanged, at what point in future time of me not bringing a product to market would you call my company a "scam"?
I am creating an analogy between patents for biologicals & the value & risks associated with business relationships in underdeveloped markets that are made and exposed as deficient by the whims of geopolitical tensions & economic gamesmanship.
The word "scam" is being tossed around too freely. Most business ideas fail to gain traction. This does not mean that their paper/debt trading or business failure delegitimizes & criminalizes the endeavor. If I wanted, I could incorporate a personal newspaper, establish credit for it, obtain a DUNS number by soliciting DUNS & Bradstreet, & then sell shares in a desperate quest to make a media empire (all while earning a meager living from the activities).
The word "scam" is being tossed around too freely. Most business ideas gain traction. This does not mean the paper/debt trading or business failure delegitimizes & criminalizes those endeavors. If I wanted, I could incorporate a personal newspaper, establish credit for it, obtain a DUNS number by soliciting DUNS & Bradstreet, & then sell shares in a desperate quest to make a media empire (all while earning a meager living from the activities).
If Dabrowski, on the other hand, has been accumulating a fortune of Bitcoin, all hands on deck.
$ALYI management's ambitious EV planning is realizable. Clearly, they are intelligent enough to understand that they must produce Audited financials & increase their accountability to shareholders & cryptocurrency owners by making themselves & the company fully subject to the broadest & finest details of regulatory oversight.
I expect the current CEO to fall on his sword implementing an increase to Authorized Shares to make sure the financials are audited. And, then, I expect the new CEO to follow up with a reverse split (to defend share price).
I expect the trading price of IQST to exceed $2 by the end of the month & for their 10k (which will be released at that time) to pave the way for a rapid climb to $5 by the end of April. As they have stated a goal of continuing mergers & acquisitions enabled by the establishment of capital formation (dilutive), I'd expect the IQST share price to be above $10 this summer & sway with the tides of efficient growth thereafter.
$IQST is experiencing rapid revenue Growth, it has no debt, it is streamlining its subsidiaries, it has marginal Outstanding Shares, & it is determined to uplist (could have joined OTCQB last summer) & that is likely to be on the nasdaq which generally requires Share price to be $3 (but their is a $2 provision). Also, IQST has tweeted that they will make an announcement about uplisting this week & have messaged their Ambassadors group on Facebook that News is also imminent.
I'll bet that these are all demonstration trades originating from the original 30000 sold yesterday by the Revolt Token Deployer. FWIW, I expect $ALYI trading to fully indicate uncertainties until institutional investors & other venture capitalists are motivated by sector heavy weights better attuned to its analytics & their information needs.
Those who haven't established their $IQST position already still have a brief opportunity to nurse local wounds & seed future hopes.
If Elon Musk / $TSLA were to get involved with the RVLT token, one would think he or they would, in part, time such investment to advance the purchasing power of potential new EV consumers. ALYI management & investors should caution their roller coastered expectations with patience.
the new MM behemoth is borrowing from the 4.3 million shares available to raid the market.
1. a) I'd feel much better about $IQST's reconstituted Russell MicroCap (RM) inclusion if its application for uplisting to the Nasdaq, as a testament to Market Efficiency, was made on March 1 because 4 to 6 weeks of processing applies to much pressure upon RM deadlines.
2. Be very careful with price forecasts from stock promoters who are only relying upon 8 weeks of data and who are not weighting seasonal (calendar) effects (especially when they let slip their 20% profit regret)
Apparently Elon Musk doesn't like stable coins.
Or did they say pegged to the dollar? Something like that Elon Musk (@elonmusk)
20, 2021Or did they say pegged to the dollar? Something like that …
— Elon Musk (@elonmusk) February 20, 2021
I am dismayed by the lack of imaginative belief of some board posters when the 1000% run up of IQST's share price since late December 2020 is considered as an exponentiating factor for the tightening of share structure's impact on its continuing bull run (despite likely naked trading by MMs).
BTW, if you are dependent upon buy the hype & sell the news trading insights of self-styled trading gurus, then know that you are being played solely for the benefit of their portfolio gains (especially in light of the fact that IQST is in the habit of stacking its news releases for sequential release.
Behaving as confident & long-run minded shareholders will help advantage IQST in identifying & capturing enterprises which offer its subsidiaries new synergies & greater revenue. If no one sells shares until IQST is $26 it will be too expensive for some time to attract the institutional investors looking to finance expansion & diversification. It is after these dilutive SPAs occur that skilled investors keenly average up their historic purchase price on saddle for the continuing long ride up.
In short, exiting too soon entails troubling dilution & risky mergers. Holding way too long, on the other hand, will stifle growth.